 |
 |
 |
 |
 |
|
|||||
|
Select Publications
Amler L et al. HER pathway gene expression analysis in a phase II study of pertuzumab + gemcitabine vs gemcitabine + placebo in patients with platinum-resistant epithelial ovarian cancer. ASCO 2008;Abstract 5552.
Burger RA et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study. Proc ASCO 2005;Abstract 5009.
Krasner CN et al. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer 2007;97(12):1618-24. Abstract
Makhija S et al. Results from a phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. ASCO 2007;Abstract 5507.
Monk BJ et al. A randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in relapsed, recurrent ovarian cancer. ESMO Congress 2008;Abstract LBA4.
National Comprehensive Cancer Network (NCCN®). NCCN clinical practice guidelines in oncology. Ovarian cancer — Version 1. 2008. Available at: http://nccn.org/professionals/physician_gls/PDF/ovarian.pdf
Sessa C et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005;23(9):1867-74. Abstract
| Table of Contents | Top of Page |
EDITOR
Neil Love, MD
INTERVIEWS
Tate Thigpen, MD
- Select publications
Ursula A Matulonis, MD
- Select publications
Robert A Burger, MD
- Select publications
Bradley J Monk, MD
- Select publications
Ovarian Cancer Update:
A CME Audio Series and Activity
 |
 |
 |
  |
